Scarica l'app Stockscreener
10.36
1.80%
-0.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Should Relay’s Zovegalisib Momentum and New Legal Forum Rules Require Action From Relay Therapeutics (RLAY) Investors? - simplywall.st
Guggenheim Raises Price Target for Relay Therapeutics (RLAY) to $22 | RLAY Stock News - GuruFocus
Can Relay Therapeutics Inc expand into new markets2026 Market Sentiment & Growth Focused Stock Reports - baoquankhu1.vn
Relay Therapeutics Files Amended and Restated Bylaws with SEC – Key Company Information and Filing Details - Minichart
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Thomas Catinazzo Sells Shares of Relay Therapeutics Inc (RLAY) - GuruFocus
Relay Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Zovegalisib Milestones To Shape The Future Of Relay Therapeutics - RTTNews
Investment Review: Can Relay Therapeutics Inc sustain its profitability2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
A Look At Relay Therapeutics (RLAY) Valuation After Earnings Update And New Shelf Registration - Sahm
Relay Therapeutics Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Wells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight Recommendation - MSN
Should I add Relay Therapeutics Inc stock to my portfolio2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
Relay Therapeutics Stock Price Rises 6% - National Today
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6%Should You Buy? - MarketBeat
Why Relay Therapeutics (RLAY) Is Up 14.8% After 2025 Beat, FDA Breakthrough Win for Zovegalisib - Sahm
Relay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Decrease in Short Interest - MarketBeat
Citizens reiterates Relay Therapeutics stock rating ahead of data By Investing.com - Investing.com Canada
Aug Levels: Is Relay Therapeutics Inc stock showing strong momentum2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status - Investing.com Nigeria
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Relay Therapeutics’ Promising Path with FDA Approvals and Revenue Growth - timothysykes.com
Bank Watch: What is the earnings history of Relay Therapeutics IncWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - Sahm
Relay Therapeutics Surges After Breakthrough Designation for Breast Cancer Treatment - StocksToTrade
Relay Therapeutics’ Q4 Financial Performance Surges Amid Breakthrough Recognition - timothysykes.com
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest - Yahoo Finance
Relay Therapeutics (RLAY) Losses Of US$276.5 Million Test Bullish Revenue Growth Narrative - simplywall.st
Relay Therapeutics stock hits 52-week high at 9.64 USD By Investing.com - Investing.com Australia
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million - AOL.com
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 61.57% Potential Upside in Precision Medicine - DirectorsTalk Interviews
RLAY: Wells Fargo Raises Price Target to $15, Maintains Overweig - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $15.00 - MarketBeat
RLAY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Relay Therapeutics Shares Jump 19% On Earnings And Pipeline Progress - Nasdaq
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High on Strong Earnings - MarketBeat
Relay Therapeutics stock hits 52-week high at 9.64 USD - Investing.com
A Look At Relay Therapeutics (RLAY) Valuation As Shares Rebound And Trade Below Analyst Targets - simplywall.st
Decoding Relay Therapeutics Inc (RLAY): A Strategic SWOT Insight - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Announces Quarterly Earnings Results - MarketBeat
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - Investing News Network
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Relay Therapeutics (RLAY) Surpasses Q4 Revenue Estimates, Eyes C - GuruFocus
Relay Therapeutics Q4 Loss Narrows, Revenue Rises; Cash Runway Into 2029 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics Posts Q4 Loss Per Share $0.32, vs. FactSet Est of $0.40 Loss - marketscreener.com
Relay Therapeutics beats Q4 revenue expectations - TradingView
Relay Therapeutics Q4 Earnings Assessment - Benzinga
Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q4 Revenue $7.0M, vs. FactSet Est of $5.0M - marketscreener.com
Relay Therapeutics (NASDAQ: RLAY) narrows 2025 loss and sets major 2026 zovegalisib data milestones - Stock Titan
Cancer drug developer lines up 2026 trial milestones backed by $555M cash - Stock Titan
Relay Therapeutics earnings in spotlight after FDA breakthrough By Investing.com - Investing.com South Africa
Relay Therapeutics earnings in spotlight after FDA breakthrough - Investing.com
Private Capital Advisors Inc. Cuts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Earnings Preview - Benzinga
Relay Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):